Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (3829)	2/15/1998 8:17:00 PM
From: JOHN W.	Read Replies (3) \| Respond to of 6136

I believe it is quite mis-leading to group all Protease Inhibitors side effects applicable to the class. You first made these accusations regarding cross resistance; stating many times that cross resistance from PI to PI were the same diregarding the preliminary in vitro data supplied by AGPH. Clearly after Chicago you were wrong, and data presented clearly indicates Viracept should be the first line therapy as it leaves follow on options if resistance should develop. Once again you tried to make this case with diabetes development that it was a characterized as a class. We are still awaiting you data regarding Nelfinavir in particular????? Now comes a side effect that was first discussed here on SI over a year ago called Cix belly, which is appropriately named. The most accurate data thus far is that 3 (previously on Crixivan) out of 109 taking nelfinavir had indications of crix-belly. I will begin the long wait for you to provide the data specific to nelfinavir to support your mysterious agenda of public enlightenment here on the AGPH thread. I am also still waiting for you to admit that you were wrong on cross resistance.